Continuous Glucose Monitor From Senseonics Earns FDA Approval For ‘Non-Adjunctive’ Claim

10 Jun 2019

Senseonics now can promote its Eversense continuous glucose monitoring system as a replacement for fingerstick testing to help patients make diabetes treatment decisions during the day, following FDA approval of a new non-adjunctive indication.

medicine, diabetes, glycemia, health care and people concept - close up of male finger with blood drop and test stripe - Image — • Source: shutterstock.com

Senseonics Holdings Inc. will soon begin marketing its Eversense continuous glucose monitoring (CGM) system in the US as an alternative to fingerstick testing to help patients make diabetes treatment decisions throughout the day.

On 6 June, the US Food and Drug Administration approved a PMA supplement for new “non-adjunctive” labeling stating that Eversense...